The stock's fall snapped a three-day winning streak.

UBS analyst Laura Sutcliffe maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – Research ...

Jarden analyst Steven Wheen maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – Research ...

Shares of ResMed Inc. RMD rose 1.67% to $254.70 Monday, on what proved to be an all-around mixed trading session for the ...

ResMed (NYSE:RMD – Get Free Report) is projected to issue its quarterly earnings data after the market closes on Thursday, ...

The investing pros at Firetrail forecast another strong year for ResMed shares in 2025. The post ResMed shares are up 42% in a year. This shows why they could still be great value appeared first on ...

ResMed’s stock has surged but faces potential risks from GLP-1 drugs. Find out why RMD stock remains a Hold as investors ...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story ...

The broker is feeling very bullish about the sleep disorder treatment company. The post Goldman Sachs tips ResMed shares to ...

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing ...